Not applicableActive Not RecruitingNCT05571618What this trial is testingThe Rechallenge of ADCs in MBC PatientsWho this might be right forBreast Cancer Fudan University 100
Not applicableStudy completedNCT01827254What this trial is testingSutent Rechallenge In mRCC PatientsWho this might be right forMetastatic Renal Cell Carcinoma Pfizer 61
Testing effectiveness (Phase 2)Looking for participantsNCT06470971What this trial is testingSiltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialWho this might be right forAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm Yuanquan Yang 40
Not applicableUnknownNCT03259009What this trial is testingRAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)Who this might be right forMetastatic Colorectal Cancer Association des Gastroentérologues Oncologues 73
Testing effectiveness (Phase 2)Study completedNCT03227926What this trial is testingRechallenge With Panitumumab Driven by RAS Dynamic of ResistanceWho this might be right forColorectal Cancer Fondazione del Piemonte per l'Oncologia 32
Testing effectiveness (Phase 2)Looking for participantsNCT06421298What this trial is testingA Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.Who this might be right forLung Cancer Jinghui Wang 30
Testing effectiveness (Phase 2)UnknownNCT05530200What this trial is testingPRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.Who this might be right forMetastatic Solid Tumor Second Affiliated Hospital of Soochow University 56
Testing effectiveness (Phase 2)UnknownNCT05325684What this trial is testingPD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerWho this might be right forEfficacySafety The Affiliated Hospital of Qingdao University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178717What this trial is testingCharacterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based CombinationsWho this might be right forColo-rectal Cancer Vall d'Hebron Institute of Oncology 25
Large-scale testing (Phase 3)Study completedNCT01151852What this trial is testingRechallenge of Imatinib in GIST Having no Effective Treatment: RIGHTWho this might be right forGastrointestinal Stromal Tumors Asan Medical Center 81
Early research (Phase 1)Not Yet RecruitingNCT06293339What this trial is testingDurability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)Who this might be right forMalaria,Falciparum Leiden University Medical Center 14
Testing effectiveness (Phase 2)UnknownNCT02296203What this trial is testingCetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).Who this might be right forMetastatic Colorectal Cancer Gruppo Oncologico del Nord-Ovest 27
Testing effectiveness (Phase 2)UnknownNCT05291156What this trial is testingCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge StrategyWho this might be right forMetastatic Colorectal Cancer University of Campania Luigi Vanvitelli 173
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07836101What this trial is testingStudy of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsWho this might be right forAny Advanced Solid Tumors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 41
Testing effectiveness (Phase 2)Study completedNCT04787341What this trial is testingPAnitumumab REchallenge Followed by REgorafenib Versus the Reverse SequenceWho this might be right forColorectal Cancer Gruppo Oncologico del Nord-Ovest 213
Testing effectiveness (Phase 2)UnknownNCT03992456What this trial is testingPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerWho this might be right forMetastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more Academic and Community Cancer Research United 12
Testing effectiveness (Phase 2)Looking for participantsNCT06663098What this trial is testingAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).Who this might be right forExtensive Stage Small Cell Lung Cancer (ES-SCLC) Gruppo Oncologico Italiano di Ricerca Clinica 142
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699237What this trial is testingPhase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)Who this might be right forExtensive Disease Small Cell Lung Cancer University of Cologne 54
Testing effectiveness (Phase 2)UnknownNCT06362694What this trial is testingStudy of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapyWho this might be right forAnaplastic Thyroid Cancer Saint Petersburg State University, Russia 10
Not applicableStudy completedNCT02192008What this trial is testingInvestigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge StudyWho this might be right forTyphoid FeverParatyphoid Fever University of Oxford 125